Longeveron (Nasdaq:LGVN) - Aktienkurs, Nachrichten und Analyse

LGVN Aktienübersicht

Longeveron Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und entwickelt Zelltherapien für altersbedingte und lebensbedrohliche Krankheiten in den Vereinigten Staaten und Japan.

Über das Unternehmen

LGVN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Belohnungen

Risikoanalyse

Stark schwankender Aktienkurs in den letzten 3 Monaten

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Erzielt weniger als 1 Million USD an Einnahmen ($978K)

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

+ 1 mehr Risiko

Longeveron Inc. Wettbewerber

Oncternal Therapeutics

NasdaqCM:ONCT

US$26.0m

Orgenesis

NasdaqCM:ORGS

US$27.4m

SAB Biotherapeutics

NasdaqCM:SABS

US$29.1m

OncoCyte

NasdaqCM:OCX

US$36.9m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Longeveron
Historical stock prices
Current Share Price	US$3.19
52 Week High	US$39.10
52 Week Low	US$0.77
Beta	0.31
1 Month Change	149.22%
3 Month Change	-27.68%
1 Year Change	-92.03%
3 Year Change	-95.57%
5 Year Change	n/a
Change since IPO	-95.70%

Aktuelle Nachrichten und Updates

Recent updates

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Jul 07

Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market

May 06

Companies Like Longeveron (NASDAQ:LGVN) Are In A Position To Invest In Growth

Apr 03

Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses

Feb 15

Longeveron: Spooky Social-Media Generated Spike Signifies Nothing

Nov 29

Is Longeveron (NASDAQ:LGVN) In A Good Position To Deliver On Growth Plans?

Nov 20

Aktionärsrenditen

	LGVN	US Biotechs	US Markt
7D	206.7%	0.1%	1.2%
1Y	-92.0%	7.1%	20.8%

Preisvolatilität

Is LGVN's price volatile compared to industry and market?
LGVN volatility
LGVN Average Weekly Movement	47.3%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2014	24	Mohamed Wa'el Hashad	longeveron.com

Longeveron Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und entwickelt in den Vereinigten Staaten und Japan Zelltherapien für altersbedingte und lebensbedrohliche Krankheiten. Das führende Prüfprodukt des Unternehmens ist LOMECEL-B, eine allogene mesenchymale Stammzellformulierung, die aus dem Knochenmark junger und gesunder erwachsener Spender gewonnen wird. Das Unternehmen führt klinische Studien der Phase 1, Phase 1/2, Phase 2a und Phase 2b in verschiedenen Indikationen durch, z. B. altersbedingte Gebrechlichkeit, Alzheimer-Krankheit und hypoplastisches Linksherzsyndrom.

Longeveron Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Longeveron im Vergleich zum Marktanteil des Unternehmens?
LGVN grundlegende Statistiken
Marktanteil	US$20.25m
Gewinn(TTM)	-US$21.62m
Umsatz(TTM)	US$978.00k

20.7x

Kurs-Umsatz-Verhältnis

-0.9x

Kurs-Gewinn-Verhältnis

Ist LGVN zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
LGVN Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$978.00k
Kosten der Einnahmen	US$504.00k
Bruttogewinn	US$474.00k
Sonstige Ausgaben	US$22.10m
Umsatz	-US$21.62m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-3.41
Bruttomarge	48.47%
Nettogewinnspanne	-2,210.84%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich LGVN auf lange Sicht entwickelt?

Historische Performance und Vergleiche

LGVN Aktienübersicht

Belohnungen

Risikoanalyse

Longeveron Inc. Wettbewerber

NasdaqCM:ONCT

US$26.0m

NasdaqCM:ORGS

US$27.4m

NasdaqCM:SABS

US$29.1m

NasdaqCM:OCX

US$36.9m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Consensus revenue estimates increase by 931%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Longeveron Inc. to Report Q1, 2024 Results on May 14, 2024

Recent updates

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Consensus revenue estimates increase by 931%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Longeveron Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates upgraded to US$5.85 loss

Price target decreased by 48% to US$37.50

New major risk - Share price stability

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million.

New major risk - Shareholder dilution

New major risk - Market cap size

Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Full year 2023 earnings: EPS misses analyst expectations

Longeveron Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $2.365 million.

Longeveron Inc. has filed a Follow-on Equity Offering in the amount of $2.195588 million.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’S Disease

Long-Term Survival Data from Longeveron’s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association

Longeveron Inc. to Report Q3, 2023 Results on Nov 10, 2023

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B™? for the Treatment of Mild Alzheimer's

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%

Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer’s Disease

Director exercised options to buy US$70k worth of stock.

New major risk - Revenue size

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q2, 2023 Results on Aug 11, 2023

Longeveron Inc. Announces the Appointment of Lisa Locklear as Chief Financial Officer, Effective July 31, 2023

Longeveron Inc. Appoints Nataliya Agafonova M.D. as Chief Medical Officer

High number of new directors

Longeveron Inc. Approves Bord Appointments

Longeveron Inc. Announces Resignation of James Clavijo as CFO

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.90 loss per share (vs US$0.90 loss in FY 2021)

Price target decreased to US$15.50

Longeveron Provides Corporate Update

Consensus forecasts updated

Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Longeveron Inc. Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’S Disease

Longeveron Inc. to Report Q3, 2022 Results on Nov 14, 2022

Longeveron Inc.: A New Approach To Treat Alzheimer's

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's Lomecel-B(TM) Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants

Longeveron spikes after FDA’s Fast Track Designation for lead candidate

Consensus revenue estimates fall by 12%

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.26 loss in 2Q 2021)

Longeveron Inc. to Report Q2, 2022 Results on Aug 12, 2022

Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Director notifies of intention to sell stock

CFO & Treasurer recently sold US$305k worth of stock

Erträge & Einnahmen